Krystal Biotech Inc
NASDAQ:KRYS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
100.42
213.66
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one KRYS stock under the Base Case scenario is 113.67 USD. Compared to the current market price of 190.4 USD, Krystal Biotech Inc is Overvalued by 40%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Krystal Biotech Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for KRYS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Krystal Biotech Inc
Balance Sheet Decomposition
Krystal Biotech Inc
Current Assets | 713.2m |
Cash & Short-Term Investments | 588.3m |
Receivables | 97.3m |
Other Current Assets | 27.5m |
Non-Current Assets | 269.2m |
Long-Term Investments | 105.9m |
PP&E | 163.1m |
Other Non-Current Assets | 203k |
Current Liabilities | 89.5m |
Accounts Payable | 5.6m |
Accrued Liabilities | 80.8m |
Other Current Liabilities | 3.2m |
Non-Current Liabilities | 6.9m |
Other Non-Current Liabilities | 6.9m |
Earnings Waterfall
Krystal Biotech Inc
Revenue
|
241.5m
USD
|
Cost of Revenue
|
-18m
USD
|
Gross Profit
|
223.5m
USD
|
Operating Expenses
|
-158.6m
USD
|
Operating Income
|
65m
USD
|
Other Expenses
|
-12.6m
USD
|
Net Income
|
52.4m
USD
|
Free Cash Flow Analysis
Krystal Biotech Inc
USD | |
Free Cash Flow | USD |
In the latest earnings call, Krystal Biotech highlighted a significant revenue increase of $83.8 million for VYJUVEK, following a successful launch that has exceeded $250 million in net revenue since its introduction. The company reported a remarkable gross margin of 92% and net income of $27.2 million or $0.95 per share. Additionally, they narrowed their full-year non-GAAP R&D and SG&A expense guidance to $115-$125 million. With $374 million in cash on hand, and plans to expand globally, including launches in Germany and Japan slated for 2025, Krystal remains optimistic about sustaining growth amid seasonal challenges.
What is Earnings Call?
KRYS Profitability Score
Profitability Due Diligence
Krystal Biotech Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Krystal Biotech Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
KRYS Solvency Score
Solvency Due Diligence
Krystal Biotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Krystal Biotech Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
KRYS Price Targets Summary
Krystal Biotech Inc
According to Wall Street analysts, the average 1-year price target for KRYS is 211.93 USD with a low forecast of 196.95 USD and a high forecast of 232.05 USD.
Dividends
Current shareholder yield for KRYS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
KRYS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Krystal Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development of redosable gene therapies to improve the lives of patients living with rare diseases. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 119 full-time employees. The company went IPO on 2017-09-20. Using its platform that is based on engineered herpes simplex virus type 1 (HSV-1), the Company create vectors that deliver therapeutic transgenes to cells of interest in multiple organ systems. The Company’s gene therapy product candidates and undertaking preclinical studies and clinical trials of B-VEC, KB105, KB301, KB104, KB407 and KB408. The firm's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, and dehydration.
Contact
IPO
Employees
Officers
The intrinsic value of one KRYS stock under the Base Case scenario is 113.67 USD.
Compared to the current market price of 190.4 USD, Krystal Biotech Inc is Overvalued by 40%.